These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 37232564)
1. The Association Between Taxane Use and Lacrimal Disorders. McGwin G; Contorno T; Vicinanzo MG; Owsley C Curr Eye Res; 2023 Sep; 48(9):873-877. PubMed ID: 37232564 [TBL] [Abstract][Full Text] [Related]
2. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy. Sodhi M; Yeung SN; Maberley D; Mikelberg F; Etminan M JAMA Ophthalmol; 2022 Sep; 140(9):880-884. PubMed ID: 35951320 [TBL] [Abstract][Full Text] [Related]
3. Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database. Wang LY; Liao LF; Lei CL; Wu Q; Guo YJ; Li Y Expert Opin Drug Saf; 2023; 22(9):833-839. PubMed ID: 37055919 [TBL] [Abstract][Full Text] [Related]
4. Epiphora in lung cancer patients receiving docetaxel: a case series. Yamagishi T; Ochi N; Yamane H; Hasebe S; Takigawa N BMC Res Notes; 2014 May; 7():322. PubMed ID: 24886618 [TBL] [Abstract][Full Text] [Related]
5. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Esmaeli B; Hidaji L; Adinin RB; Faustina M; Coats C; Arbuckle R; Rivera E; Valero V; Tu SM; Ahmadi MA Cancer; 2003 Aug; 98(3):504-7. PubMed ID: 12879466 [TBL] [Abstract][Full Text] [Related]
6. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Esmaeli B; Hortobagyi G; Esteva F; Valero V; Ahmadi MA; Booser D; Ibrahim N; Delpassand E; Arbuckle R Ann Oncol; 2002 Feb; 13(2):218-21. PubMed ID: 11885997 [TBL] [Abstract][Full Text] [Related]
7. Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Esmaeli B; Burnstine MA; Ahmadi MA; Prieto VG Ophthalmic Plast Reconstr Surg; 2003 Jul; 19(4):305-8. PubMed ID: 12878879 [TBL] [Abstract][Full Text] [Related]
8. A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis. Leyssens B; Wildiers H; Lobelle JP; Gillis A; Paridaens R; Mombaerts I Ann Oncol; 2010 Feb; 21(2):419-423. PubMed ID: 19622592 [TBL] [Abstract][Full Text] [Related]
9. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Esmaeli B; Valero V; Ahmadi MA; Booser D Ophthalmology; 2001 May; 108(5):994-5. PubMed ID: 11320034 [TBL] [Abstract][Full Text] [Related]
10. Management of excessive tearing as a side effect of docetaxel. Esmaeli B Clin Breast Cancer; 2005 Feb; 5(6):455-7. PubMed ID: 15748466 [TBL] [Abstract][Full Text] [Related]
11. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394 [TBL] [Abstract][Full Text] [Related]
12. Epiphora induced by intermittent docetaxel (taxotere) in patients with non-small cell lung cancer. Spell DW; Estephan FF; Lin JT; Jones DV Cancer Invest; 2003; 21(4):550-2. PubMed ID: 14533445 [No Abstract] [Full Text] [Related]
13. Assessing taxane-associated adverse events using the FDA adverse event reporting system database. Lao DH; Chen Y; Fan J; Zhang JZ Chin Med J (Engl); 2021 Jun; 134(12):1471-1476. PubMed ID: 34074841 [TBL] [Abstract][Full Text] [Related]
14. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer. Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088 [TBL] [Abstract][Full Text] [Related]
15. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Esmaeli B; Hortobagyi GN; Esteva FJ; Booser D; Ahmadi MA; Rivera E; Arbuckle R; Delpassand E; Guerra L; Valero V Ophthalmology; 2002 Jun; 109(6):1188-91. PubMed ID: 12045065 [TBL] [Abstract][Full Text] [Related]
16. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304 [TBL] [Abstract][Full Text] [Related]
17. [A Retrospective Analysis of Epiphora Due to Docetaxel]. Noguchi Y; Kawashima Y; Kawara H; Tokuyama Y; Tamura Y; Uchiyama K; Shimizu Y Gan To Kagaku Ryoho; 2016 Jun; 43(6):737-41. PubMed ID: 27306811 [TBL] [Abstract][Full Text] [Related]
18. Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Raisch DW; Campbell W; Garg V; Qureshi ZP; Bookstaver PB; Norris LB; Bennett CL Expert Opin Drug Saf; 2011 Jul; 10(4):521-8. PubMed ID: 21595611 [TBL] [Abstract][Full Text] [Related]
19. Ophthalmic adverse effects of taxanes: The Mayo Clinic experience. Fortes BH; Liou H; Dalvin LA Eur J Ophthalmol; 2022 Jan; 32(1):602-611. PubMed ID: 33148049 [TBL] [Abstract][Full Text] [Related]
20. Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly. Ahmadi MA; Esmaeli B Arch Ophthalmol; 2001 Dec; 119(12):1802-4. PubMed ID: 11735790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]